Cisplatin Ebewe (Cisplatin)

What Is Cisplatin Ebewe and What Is It Used For?

Cisplatin Ebewe is a platinum-based cytotoxic (anticancer) medication used to treat several types of cancer. It belongs to a class of drugs called alkylating-like agents that work by damaging cancer cell DNA, preventing the cells from dividing and ultimately leading to their death. Cisplatin can be used alone but is most commonly given in combination with other chemotherapy drugs.

Cisplatin was one of the first platinum-based compounds discovered to have anticancer properties, and its introduction in the 1970s revolutionized the treatment of several solid tumors. Today, cisplatin remains one of the most widely used and effective chemotherapy agents in the world. It is included on the World Health Organization (WHO) Model List of Essential Medicines, reflecting its fundamental importance in cancer care globally.

The active substance in Cisplatin Ebewe is cisplatin (also known as cis-diamminedichloroplatinum(II) or CDDP), a planar inorganic complex containing a central platinum atom. Each milliliter of the solution contains 1 mg of cisplatin. The product is supplied as a clear, colorless to slightly yellowish concentrate for solution for infusion in glass vials containing 10 ml (10 mg), 20 ml (20 mg), 50 ml (50 mg), or 100 ml (100 mg) of cisplatin.

Cisplatin Ebewe is approved for the treatment of the following cancers, either as monotherapy or in combination with other anticancer agents:

• Testicular cancer: Both seminoma and non-seminomatous germ cell tumors. Cisplatin-based regimens such as BEP (bleomycin, etoposide, cisplatin) have transformed testicular cancer into one of the most curable solid tumors, achieving overall cure rates exceeding 90% in early-stage disease
• Ovarian cancer: Epithelial ovarian carcinoma, typically used in combination with paclitaxel or cyclophosphamide as first-line treatment following surgical debulking. According to ESMO guidelines, platinum-based chemotherapy remains the standard of care
• Non-small cell lung cancer (NSCLC): Used in combination regimens for advanced or metastatic NSCLC. The NCCN Clinical Practice Guidelines recommend cisplatin-based doublets as a standard first-line chemotherapy option
• Head and neck squamous cell carcinoma: Used both as induction chemotherapy and concurrently with radiotherapy for locally advanced disease. Concurrent cisplatin-radiation is considered a standard-of-care approach according to international guidelines

Your treating oncologist may also prescribe cisplatin for other cancer types not listed above, as it has demonstrated activity against a wide range of malignancies including bladder cancer, cervical cancer, esophageal cancer, and mesothelioma. The decision to use cisplatin depends on the specific type and stage of cancer, your overall health status, and the treatment goals.

How Cisplatin Works

Cisplatin exerts its anticancer effect primarily through the formation of platinum-DNA adducts. Once cisplatin enters the bloodstream and reaches cancer cells, it undergoes a chemical activation process inside the cell where chloride ligands are replaced by water molecules. This activated form of cisplatin then reacts with DNA, forming cross-links primarily between adjacent guanine bases on the same DNA strand (intrastrand cross-links) and, to a lesser extent, between the two complementary DNA strands (interstrand cross-links).

These platinum-DNA adducts distort the three-dimensional structure of the DNA helix, preventing normal DNA replication and transcription. The cell's DNA repair mechanisms attempt to fix this damage, but when the damage is too extensive, the cell activates programmed cell death pathways (apoptosis). Because cancer cells typically divide more rapidly than most normal cells, they are generally more susceptible to the DNA-damaging effects of cisplatin. However, this mechanism also explains why cisplatin affects rapidly dividing normal cells, particularly in the bone marrow, gastrointestinal tract, and hair follicles.

What Should You Know Before Taking Cisplatin Ebewe?

Before receiving cisplatin, your doctor will perform comprehensive blood tests, kidney function assessments, and hearing tests. Cisplatin must not be used if you have significant kidney impairment, dehydration, severe bone marrow suppression, hearing loss, or if you are breastfeeding. Several medications can interact dangerously with cisplatin, and effective contraception is required during and after treatment.

Cisplatin is a potent chemotherapy agent with a well-characterized toxicity profile. Your oncologist and healthcare team will carefully evaluate whether cisplatin is appropriate for you, taking into account your overall health, kidney function, hearing status, blood counts, and any other medications you may be taking. Understanding the contraindications, warnings, and potential interactions is essential for safe treatment.

Contraindications

You must not receive Cisplatin Ebewe if any of the following apply:

• Allergy to cisplatin or platinum compounds: If you are allergic to cisplatin, any other platinum-containing drug (such as carboplatin or oxaliplatin), or any of the other ingredients in the formulation
• Kidney problems: If you have significant renal impairment, as cisplatin is primarily eliminated through the kidneys and can cause further kidney damage
• Dehydration: Adequate hydration is essential for safe cisplatin administration; the drug must not be given to dehydrated patients
• Low blood cell counts: If you have pre-existing bone marrow suppression with critically low levels of white blood cells, red blood cells, or platelets
• Hearing impairment: If you already have significant hearing loss, as cisplatin can cause further irreversible damage to hearing
• Breastfeeding: Cisplatin must not be used during breastfeeding, as it may pass into breast milk and harm the nursing infant
• Yellow fever vaccine: Vaccination with yellow fever vaccine is contraindicated during cisplatin treatment due to the risk of fatal systemic vaccine disease
• Concurrent phenytoin use for prophylaxis: The combination with phenytoin is contraindicated; cisplatin reduces the effectiveness of phenytoin

Warnings and Precautions

Talk to your doctor or nurse before receiving Cisplatin Ebewe. Your healthcare team will implement several monitoring measures and precautions during your treatment:

• Blood tests: Your doctor will regularly check levels of calcium, sodium, potassium, and magnesium in your blood, as well as your complete blood count and liver and kidney function, before each treatment cycle
• Specialist supervision: Cisplatin must only be administered under the strict supervision of a physician experienced in cancer chemotherapy, in a hospital or clinical setting equipped to manage potential complications
• Hearing tests: Audiometric testing will be performed before each treatment cycle to monitor for early signs of hearing damage
• Pre-existing nerve disease: If you have peripheral neuropathy not caused by cisplatin, inform your doctor as the drug may worsen nerve symptoms
• Infection: If you have an active infection, consult your doctor before treatment, as cisplatin suppresses the immune system
• Nausea and vomiting: If you experience vomiting or diarrhea after treatment, the fluid loss must be compensated to protect your kidneys
• Skin contact: If cisplatin solution spills on your skin, wash the area immediately with soap and water, as it can cause local tissue irritation
• Extravasation: If cisplatin is accidentally injected outside the vein during infusion, the infusion must be stopped immediately, as leakage into surrounding tissue can cause severe damage including cellulitis, fibrosis, and tissue necrosis

Pregnancy, Breastfeeding, and Fertility

Cisplatin poses significant risks to reproductive health and fetal development. If you are pregnant or think you may be pregnant, or if you are planning to have children, speak to your doctor before starting treatment.

• Pregnancy: Cisplatin must not be used during pregnancy unless clearly necessary for the mother, as it can cause serious harm to the developing baby. Animal studies have shown that cisplatin is teratogenic (can cause birth defects) and embryotoxic
• Contraception: Women of childbearing potential must use effective contraception during treatment and for at least 7 months after the last dose of cisplatin
• Breastfeeding: Cisplatin is contraindicated during breastfeeding. You must not breastfeed while receiving cisplatin treatment
• Male fertility: Men should not father children during treatment and for at least 4 months after the last dose. Cisplatin can significantly reduce or eliminate sperm production, which may be permanent. Men are strongly advised to seek sperm banking before beginning treatment
• Female fertility: Cisplatin may affect ovulation and menstrual function. Discuss fertility preservation options with your oncologist before starting treatment

Driving and Operating Machinery

Do not drive or operate machinery that requires your full attention during cisplatin treatment, as the drug may cause drowsiness and nausea. You are responsible for assessing whether you are fit to drive or perform work requiring alertness. The side effects described in this article may affect your ability to do so safely.

Sodium Content

Cisplatin Ebewe contains sodium chloride as an excipient. The sodium content varies by vial size:

• 10 ml vial: 35 mg sodium (1.75% of the WHO recommended maximum daily intake for adults)
• 20 ml vial: 71 mg sodium (3.55% of maximum daily intake)
• 50 ml vial: 177 mg sodium (8.85% of maximum daily intake)
• 100 ml vial: 354 mg sodium (17.7% of maximum daily intake)

This should be taken into consideration for patients on a sodium-restricted diet, particularly when larger vial sizes or multiple vials are used.

How Does Cisplatin Ebewe Interact with Other Drugs?

Cisplatin has clinically significant interactions with many medications. Drugs that are toxic to the kidneys or ears can have their harmful effects amplified when combined with cisplatin. Tell your doctor about all medications you are taking, including prescription drugs, over-the-counter medicines, and herbal supplements, before starting cisplatin therapy.

Drug interactions with cisplatin can result in increased toxicity, reduced treatment efficacy, or both. Your oncologist will carefully review your medication list before each treatment cycle. Some medications may need to be adjusted, substituted, or temporarily discontinued during cisplatin therapy. The following sections detail the most clinically important interactions.

Major Interactions

These interactions can have serious or life-threatening consequences and typically require dose adjustments, enhanced monitoring, or avoidance of the combination:

Other Notable Interactions

The following interactions are clinically relevant and may require monitoring or dose adjustments:

• Myelosuppressive drugs or radiation therapy: Concurrent bone marrow-suppressing medications or radiotherapy can worsen cisplatin's effects on the bone marrow, increasing the risk of severe infection, bleeding, and anemia
• Bleomycin and methotrexate: The toxic effects of cisplatin may be enhanced when combined with other cytotoxic agents
• Antihypertensive medications (furosemid, hydralazine, diazoxide, propranolol): May increase the nephrotoxic effect of cisplatin
• Ifosfamide: The combination may result in increased hearing loss or additional kidney damage
• Bleomycin and vinblastine: This combination can lead to pale or bluish discoloration of fingers and toes (Raynaud's phenomenon), indicating impaired circulation
• Gout medications (allopurinol, colchicine, probenecid, sulfinpyrazone): Dosage adjustments of these medications may be required during cisplatin treatment, as cisplatin can increase uric acid levels
• Antihistamines (buclizine, cyclizine, meclizine, phenothiazines): These may mask the early signs of hearing damage (dizziness, tinnitus) during cisplatin treatment
• Pyridoxine and hexamethylmelamine: May reduce the effectiveness of cisplatin treatment
• Bleomycin and etoposide: This combination may decrease lithium levels in the blood; lithium levels should be monitored regularly
• Anticoagulants (warfarin, heparin): Cisplatin may affect the efficacy of blood-thinning medications; coagulation parameters should be monitored more frequently
• Cyclosporine: Cisplatin and cyclosporine together may suppress the immune system excessively and increase the risk of abnormal lymphocyte proliferation
• Penicillamine: May reduce the therapeutic effect of cisplatin

What Is the Correct Dosage of Cisplatin Ebewe?

Cisplatin dosage is calculated based on body surface area (BSA) in mg/m² and varies depending on the type of cancer being treated and whether cisplatin is used alone or in combination with other drugs. Typical doses range from 20 to 120 mg/m² per cycle, administered every 3–4 weeks. Cisplatin is given exclusively as an intravenous infusion in a hospital setting.

Cisplatin must only be prescribed and administered by specialist physicians experienced in cancer chemotherapy. The concentrate is diluted with sodium chloride solution, or a sodium chloride solution containing glucose or mannitol, before administration. The recommended dose depends on the patient's general condition, the expected treatment response, and whether cisplatin is being used as a single agent or in combination with other anticancer drugs.

Standard Dosing Regimens

Hydration Protocol

To prevent or minimize kidney damage, an extensive hydration protocol is followed for every cisplatin infusion. Before treatment, patients receive 1–2 liters of intravenous saline over 2–4 hours. During and after the infusion, additional fluids are administered, and patients are encouraged to drink large amounts of water during the 24 hours following treatment. Mannitol or furosemide may be used to maintain adequate urine output. The target urine output is typically at least 100 ml per hour during and for several hours after the infusion.

Administration

Cisplatin is administered exclusively by intravenous infusion. The concentrate must never be injected undiluted. It is diluted with 0.9% sodium chloride solution or appropriate mixtures containing sodium chloride. The prepared infusion is given through an intravenous line over a period determined by the specific regimen, typically 30 minutes to several hours depending on the dose.

Overdose

Your treating physician will ensure that you receive the correct dose for your condition. In the event of an accidental overdose, side effects may be amplified, particularly kidney damage, liver damage, hearing loss, severe bone marrow suppression, nausea and vomiting, and visual disturbances. There is no specific antidote for cisplatin overdose; treatment is supportive and symptomatic. Immediate measures include aggressive hydration and close monitoring of organ function. If you suspect that you have received too much cisplatin, contact your healthcare team immediately.

What Are the Side Effects of Cisplatin Ebewe?

Like all chemotherapy drugs, cisplatin can cause side effects, although not everyone experiences all of them. The most common side effects include nausea and vomiting, bone marrow suppression (causing low blood counts), kidney damage, and hearing changes. Many side effects can be prevented or managed with appropriate supportive care. Contact your doctor immediately if you experience severe or unexpected symptoms.

The side effects of cisplatin are dose-dependent and cumulative, meaning they may become more pronounced with repeated treatment cycles. Your healthcare team will implement a comprehensive supportive care plan including anti-nausea medications, intravenous hydration, and regular monitoring to minimize the impact of these effects. Below is a detailed overview of reported side effects, organized by frequency.

How Should You Store Cisplatin Ebewe?

Cisplatin Ebewe is stored and handled by healthcare professionals in hospital settings. The unopened product should be stored below 25°C, protected from cold (do not freeze), and kept in the outer carton to protect from light. Patients do not typically need to store this medication at home.

As Cisplatin Ebewe is a hospital-administered medication, storage is managed by pharmacy and nursing staff. However, understanding proper storage conditions is important for ensuring the medication's effectiveness and safety. The following storage requirements apply:

• Temperature: Store at or below 25°C (77°F)
• Cold protection: Do not refrigerate or freeze. Cold temperatures can cause precipitation of the active ingredient
• Light protection: Keep the vials in the outer carton to protect from light, as cisplatin is light-sensitive
• Shelf life: Do not use after the expiration date printed on the carton and vial label (EXP). The expiration date refers to the last day of that month
• Visual inspection: Do not use if you notice any visible deterioration, discoloration, or particles in the solution. Only clear, colorless to slightly yellowish solutions should be used
• Keep out of reach of children

After Opening

Storage requirements after the vial has been opened depend on the vial size:

• 10 ml and 20 ml vials: Single-use only. Discard any unused contents immediately. Withdraw the solution from the vial immediately before use
• 50 ml and 100 ml vials: Chemical and physical in-use stability has been demonstrated for 28 days when stored at room temperature protected from light. From a microbiological standpoint, the product should be used immediately unless the method of opening excludes the risk of microbial contamination

After Dilution

The diluted infusion solution (at a final concentration of 0.1 mg/ml cisplatin) has demonstrated chemical and physical stability for 48 hours when stored at 2–8°C protected from sunlight, when prepared with the approved diluents (0.9% sodium chloride, sodium chloride/glucose mixture, or sodium chloride/mannitol mixture). From a microbiological standpoint, the diluted product should ideally be used immediately.

What Does Cisplatin Ebewe Contain?

Each milliliter of Cisplatin Ebewe contains 1 mg of cisplatin as the active substance. The other ingredients are sodium chloride, dilute hydrochloric acid, and water for injections. The product is available in 10 ml, 20 ml, 50 ml, and 100 ml glass vials.

Cisplatin Ebewe has a simple formulation designed to maintain the stability and solubility of the active ingredient:

Available Pack Sizes

Cisplatin Ebewe is available in the following presentations:

• Packs of 1, 5, or 10 vials of 10 ml (containing 10 mg cisplatin each)
• Packs of 1, 5, or 10 vials of 20 ml (containing 20 mg cisplatin each)
• Packs of 1, 5, or 10 vials of 50 ml (containing 50 mg cisplatin each)
• Packs of 1, 5, or 10 vials of 100 ml (containing 100 mg cisplatin each)

Not all pack sizes may be marketed in all countries. The vials are packaged with or without protective sleeves (Onco-Safe or protective film), which provide additional safety for pharmacy and healthcare staff during transport. These protective covers do not come into contact with the medicine itself.

Incompatibilities

Important preparation notes for healthcare professionals:

• Cisplatin must not be diluted with glucose 5% solution alone or mannitol 5% solution alone; sodium chloride must always be present in the diluent
• Antioxidants (such as sodium bisulfite), bicarbonate (sodium bicarbonate), sulfates, fluorouracil, and paclitaxel can inactivate cisplatin in the infusion set
• All equipment must be aluminum-free, as cisplatin reacts with aluminum to form a black platinum precipitate

Frequently Asked Questions About Cisplatin Ebewe